

Chester A Mathis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2303878/publications.pdf>

Version: 2024-02-01

254
papers

36,940
citations

3933

88
h-index

3106

187
g-index

268
all docs

268
docs citations

268
times ranked

22434
citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. <i>Journal of Neurochemistry</i> , 2023, 164, 364-400.	3.9	7
2	Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	5.0	39
3	Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90+. <i>Alzheimer's and Dementia</i> , 2022, , .	0.8	2
4	¹¹ C-PiB PET can underestimate brain amyloid- β burden when cotton wool plaques are numerous. <i>Brain</i> , 2022, 145, 2161-2176.	7.6	8
5	Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. <i>Biological Psychiatry</i> , 2022, 92, 791-799.	1.3	17
6	Joint β -label fusion brain atlases for dementia research in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	1
7	Development of a PET radioligand selective for cerebral amyloid angiopathy. <i>Nuclear Medicine and Biology</i> , 2021, 92, 85-96.	0.6	6
8	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321.	7.9	47
9	Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. <i>ACS Chemical Neuroscience</i> , 2021, 12, 596-602.	3.5	29
10	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740.	2.7	9
11	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. <i>NeuroImage</i> , 2021, 228, 117728.	4.2	15
12	An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1065-1078.	2.6	5
13	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. <i>Brain Sciences</i> , 2021, 11, 1180.	2.3	0
14	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	5.0	21
15	Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2020, 78, 134-144.	5.8	38
16	Associations of equol-producing status with white matter lesion and amyloid- β deposition in cognitively normal elderly Japanese. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12089.	3.7	10
17	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 140, 463-476.	7.7	34
18	Evaluation of amyloid and tau PET quantitation methods using a 3D-printed anatomically accurate brain phantom. <i>Alzheimer's and Dementia</i> , 2020, 16, e045455.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Amyloid accumulation in Down syndrome measured with amyloid load. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12020.	2.4	19
20	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. <i>Neurobiology of Aging</i> , 2020, 94, 111-120.	3.1	15
21	Relationship of amyloid- β 42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. <i>Brain Communications</i> , 2020, 2, fcz038.	3.3	10
22	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12138.	2.4	7
23	Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. <i>Communications in Computer and Information Science</i> , 2020, , 367-379.	0.5	1
24	[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline. <i>Frontiers in Neurology</i> , 2019, 10, 831.	2.4	14
25	Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1360-1371.	1.2	9
26	Effect of S-equol and Soy Isoflavones on Heart and Brain. <i>Current Cardiology Reviews</i> , 2019, 15, 114-135.	1.5	56
27	Association Between Amyloid- β , Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1753-1760.	3.6	8
28	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PiB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.8	155
29	Comparison of longitudinal $A\beta$ in nondemented elderly and Down syndrome. <i>Neurobiology of Aging</i> , 2019, 73, 171-176.	3.1	13
30	Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women. <i>Neurobiology of Aging</i> , 2019, 76, 141-150.	3.1	6
31	Quantification of 5-HT _{1A} and 5-HT _{2A} receptor Binding in Depressed Suicide Attempters and Non-Attempters. <i>Archives of Suicide Research</i> , 2019, 23, 122-133.	2.3	11
32	Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. <i>Biological Psychiatry</i> , 2018, 83, 707-714.	1.3	24
33	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. <i>Neurology</i> , 2018, 90, e1920-e1928.	1.1	36
34	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. <i>Alzheimer's and Dementia</i> , 2018, 14, 743-750.	0.8	51
35	An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (<i>R</i>)-(α)- <i>O</i> -desmethylvenlafaxine and racemic <i>O</i> -desmethylvenlafaxine. <i>Synapse</i> , 2018, 72, e22021.	1.2	6
36	Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88.	9.0	33

#	ARTICLE	IF	CITATIONS
37	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A β load. <i>NeuroImage: Clinical</i> , 2018, 19, 182-189.	2.7	13
38	Sleep moderates the relationship between amyloid beta and memory recall. <i>Neurobiology of Aging</i> , 2018, 71, 142-148.	3.1	31
39	The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 977-984.	1.2	5
40	Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 551-560.	1.2	16
41	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 1-9.	2.4	49
42	Pathological correlations of [F β 18]AV β 451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	5.3	174
43	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	4.6	91
44	Association of Brain Amyloid- β 2 With Slow Gait in Elderly Individuals Without Dementia. <i>JAMA Neurology</i> , 2017, 74, 82.	9.0	66
45	Dopaminergic activity and altered reward modulation in anorexia nervosa—insight from multimodal imaging. <i>International Journal of Eating Disorders</i> , 2017, 50, 593-596.	4.0	21
46	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- β 2 Burden in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 631-644.	2.6	23
47	[F β 18]AV β 451 positron emission tomography retention in choroid plexus: More than a coefficient—binding. <i>Annals of Neurology</i> , 2016, 80, 307-308.	5.3	66
48	Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw211.	3.6	12
49	Tenascin-C Is Associated with Cored Amyloid- β 2 Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 868-876.	1.7	31
50	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1316-1322.	5.0	161
51	Post-mortem histopathology underlying β 2-amyloid PET imaging following flutemetamol F 18 injection. <i>Acta Neuropathologica Communications</i> , 2016, 4, 130.	5.2	76
52	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 57-87.	4.6	16
53	The effects of normal aging on amyloid- β 2 deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2016, 12, 380-390.	0.8	65
54	Comparison of qualitative and quantitative imaging characteristics of [11 C]PiB and [18 F]flutemetamol in normal control and Alzheimer's subjects. <i>NeuroImage: Clinical</i> , 2015, 9, 592-598.	2.7	48

#	ARTICLE	IF	CITATIONS
55	Validating novel tau positron emission tomography tracer ^{18}F -AV-1451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	5.3	535
56	Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S151-S159.	2.6	80
57	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.8	603
58	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2015, 14, 804-813.	10.2	91
59	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 1021.	9.0	71
60	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. <i>Alzheimer's and Dementia</i> , 2015, 11, 757-771.	0.8	199
61	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 985-993.	1.2	112
62	Relative ^{11}C -PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ^{15}O -Water and ^{11}C -PiB PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1199-1205.	5.0	62
63	Amyloid- β ^{11}C -PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.1	136
64	Amyloid Imaging With Carbon 11- ^{11}C -Labeled Pittsburgh Compound B for Traumatic Brain Injury. <i>JAMA Neurology</i> , 2014, 71, 23.	9.0	132
65	Arterial Stiffness and β -Amyloid Progression in Nondemented Elderly Adults. <i>JAMA Neurology</i> , 2014, 71, 562.	9.0	152
66	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	9.0	112
67	Markers of cholesterol transport are associated with amyloid deposition in the brain. <i>Neurobiology of Aging</i> , 2014, 35, 802-807.	3.1	62
68	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. <i>Neurology</i> , 2014, 83, 1804-1811.	1.1	46
69	Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. <i>Brain</i> , 2014, 137, 3327-3338.	7.6	130
70	Association of plasma and cortical amyloid beta is modulated by APOE ϵ 4 status. <i>Alzheimer's and Dementia</i> , 2014, 10, e9-e18.	0.8	43
71	Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584.	3.1	166
72	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2013, 15, 585-595.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309
74	Cognitive aging in persons with minimal amyloid- β^2 and white matter hyperintensities. Neuropsychologia, 2013, 51, 2202-2209.	1.6	31
75	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatry Research - Neuroimaging, 2013, 211, 160-168.	1.8	71
76	Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. NeuroImage, 2013, 71, 207-215.	4.2	77
77	Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. Neuron, 2013, 79, 1035-1037.	8.1	13
78	Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β^2 -amyloid plaque binding agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1720-1726.	2.2	18
79	Amyloid- β^2 Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. Journal of Nuclear Medicine, 2013, 54, 70-77.	5.0	364
80	Cognitive trajectories associated with β^2 -amyloid deposition in the oldest-old without dementia. Neurology, 2013, 80, 1378-1384.	1.1	77
81	Pulse wave velocity is associated with β^2 -amyloid deposition in the brains of very elderly adults. Neurology, 2013, 81, 1711-1718.	1.1	156
82	Positron emission tomography radioligands for <i>in vivo</i> imaging of A β^2 plaques. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 89-95.	1.0	53
83	In vivo assessment of amyloid- β^2 deposition in nondemented very elderly subjects. Annals of Neurology, 2013, 73, 751-761.	5.3	89
84	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	2.0	78
85	In Vivo Evidence for Low Striatal Vesicular Monoamine Transporter 2 (VMAT2) Availability in Cocaine Abusers. American Journal of Psychiatry, 2012, 169, 55-63.	7.2	44
86	Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathologica, 2012, 124, 823-831.	7.7	98
87	Amyloid imaging in dementias with atypical presentation. , 2012, 8, 389-398.		46
88	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer's and Dementia, 2012, 8, 496-501.	0.8	116
89	Preventive immunization of aged and juvenile non-human primates to beta-amyloid. Journal of Neuroinflammation, 2012, 9, 84.	7.2	22
90	Development of Positron Emission Tomography β^2 -Amyloid Plaque Imaging Agents. Seminars in Nuclear Medicine, 2012, 42, 423-432.	4.6	155

#	ARTICLE	IF	CITATIONS
91	Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. <i>Journal of Translational Medicine</i> , 2012, 10, .	4.4	1
92	[11C]flumazenil Binding Is Increased in a Dose-Dependent Manner with Tiagabine-Induced Elevations in GABA Levels. <i>PLoS ONE</i> , 2012, 7, e32443.	2.5	37
93	Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2012, 45, 263-271.	4.0	47
94	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. <i>Brain Imaging and Behavior</i> , 2012, 6, 1-15.	2.1	47
95	A β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
96	Human Biodistribution and Dosimetry of the PET Radioligand [11C]Flumazenil (FMZ). <i>Molecular Imaging and Biology</i> , 2012, 14, 115-122.	2.6	5
97	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. <i>Acta Neuropathologica</i> , 2012, 123, 433-447.	7.7	78
98	Binding Potency of Paroxetine Analogues for the 5-Hydroxytryptamine Uptake Complex*. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 801-805.	2.4	18
99	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. <i>NeuroImage</i> , 2011, 55, 933-941.	4.2	47
100	Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. <i>Neurobiology of Aging</i> , 2011, 32, 2123-2130.	3.1	39
101	Binding Potency of 6-Nitroquipazine Analogues for the 5-Hydroxytryptamine Reuptake Complex. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 46, 751-754.	2.4	13
102	Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [¹¹ C]FLB 457: Reproducibility studies. <i>Synapse</i> , 2011, 65, 35-40.	1.2	41
103	Evaluation of dopamine D _{2/3} -specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹ C]FLB 457: Implications for measuring cortical dopamine release. <i>Synapse</i> , 2011, 65, 991-997.	1.2	35
104	Imaging of dopamine D _{2/3} agonist binding in cocaine dependence: A [¹¹ C]NPA positron emission tomography study. <i>Synapse</i> , 2011, 65, 1344-1349.	1.2	28
105	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	5.3	730
106	5-HT _{1A} receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. <i>International Journal of Eating Disorders</i> , 2011, 44, 477-487.	4.0	33
107	Spatial patterns of brain amyloid- β burden and atrophy rate associations in mild cognitive impairment. <i>Brain</i> , 2011, 134, 1077-1088.	7.6	97
108	In Vivo Fibrillar β -Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults. <i>Archives of Neurology</i> , 2011, 68, 232-40.	4.5	102

#	ARTICLE	IF	CITATIONS
109	11C-PiB PET assessment of change in fibrillar amyloid- β^2 load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , 2010, 9, 363-372.	10.2	674
110	No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [¹¹ C]FLB 457 in the human cortex. <i>Synapse</i> , 2010, 64, 879-885.	1.2	14
111	A Comparative Evaluation of the Dopamine D _{2/3} Agonist Radiotracer [¹¹ C]-N-Propyl-norapomorphine and Antagonist [¹¹ C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 533-539.	2.5	78
112	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ^4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884.	1.3	103
113	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , 2010, 31, 1284-1303.	3.1	127
114	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. <i>Alzheimer's and Dementia</i> , 2010, 6, 221-229.	0.8	464
115	Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. <i>Journal of Nuclear Medicine</i> , 2009, 50, 348-355.	5.0	108
116	Basal Cerebral Metabolism May Modulate the Cognitive Effects of A β^2 in Mild Cognitive Impairment: An Example of Brain Reserve. <i>Journal of Neuroscience</i> , 2009, 29, 14770-14778.	3.6	217
117	Fibrillar amyloid- β^2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6820-6825.	7.1	700
118	Carbon 11- ¹⁴ C-Labeled Pittsburgh Compound B and Carbon 11- ¹⁴ C-Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 60-7.	4.5	151
119	Episodic memory loss is related to hippocampal-mediated A β^2 deposition in elderly subjects. <i>Brain</i> , 2009, 132, 1310-1323.	7.6	596
120	Tiagabine Increases [¹¹ C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects. <i>Neuropsychopharmacology</i> , 2009, 34, 624-633.	5.4	70
121	Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 814-817.	5.0	17
122	Amyloid imaging in mild cognitive impairment subtypes. <i>Annals of Neurology</i> , 2009, 65, 557-568.	5.3	309
123	Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. <i>Synapse</i> , 2009, 63, 447-461.	1.2	127
124	Positron emission tomography imaging of D _{2/3} agonist binding in healthy human subjects with the radiotracer [¹¹ C]-N-Propyl-norapomorphine: Preliminary evaluation and reproducibility studies. <i>Synapse</i> , 2009, 63, 574-584.	1.2	24
125	Synthesis and β^2 -amyloid binding properties of rhenium 2-phenylbenzothiazoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2258-2262.	2.2	37
126	PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. <i>Neurobiology of Aging</i> , 2009, 30, 1217-1226.	3.1	118

#	ARTICLE	IF	CITATIONS
127	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. <i>Neurobiology of Aging</i> , 2009, 30, 1902-1909.	3.1	89
128	Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. <i>Nuclear Medicine and Biology</i> , 2009, 36, 235-237.	0.6	37
129	Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2009, 65, 927-934.	1.3	256
130	Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. , 2009, , 119-147.		9
131	Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. <i>Journal of Rehabilitation Research and Development</i> , 2009, 46, 717.	1.6	80
132	Serotonin transporter binding after recovery from eating disorders. <i>Psychopharmacology</i> , 2008, 197, 521-522.	3.1	3
133	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. <i>Journal of Neuroscience Methods</i> , 2008, 172, 277-282.	2.5	75
134	Longitudinal in Vivo Positron Emission Tomography Imaging of Infected and Activated Brain Macrophages in a Macaque Model of Human Immunodeficiency Virus Encephalitis Correlates with Central and Peripheral Markers of Encephalitis and Areas of Synaptic Degeneration. <i>American Journal of Pathology</i> , 2008, 172, 1603-1616.	3.8	44
135	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633.	4.2	201
136	Comparison of the binding of ^{18}F -PiB and PiB in human brain homogenates. <i>NeuroImage</i> , 2008, 41, T113-T114.	4.2	8
137	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. <i>Archives of Neurology</i> , 2008, 65, 1509.	4.5	923
138	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. <i>Brain</i> , 2008, 131, 1630-1645.	7.6	837
139	Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1465-1471.	5.0	59
140	Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance. <i>Journal of Neuroscience</i> , 2008, 28, 4283-4292.	3.6	414
141	^{11}C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	7.6	819
142	Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 261-268.	1.3	119
143	Whatever Happened to Pittsburgh Compound-A?. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 198-203.	1.3	9
144	The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. <i>Current Opinion in Neurology</i> , 2008, 21, 683-687.	3.6	85

#	ARTICLE	IF	CITATIONS
145	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844.	7.6	739
146	Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. <i>Journal of Neuroscience</i> , 2007, 27, 6174-6184.	3.6	358
147	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. <i>Archives of Neurology</i> , 2007, 64, 431.	4.5	326
148	Serotonin-1A receptor imaging in recurrent depression: replication and literature review. <i>Nuclear Medicine and Biology</i> , 2007, 34, 865-877.	0.6	341
149	Impact of amyloid imaging on drug development in Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2007, 34, 809-822.	0.6	115
150	The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging. <i>Experimental Neurology</i> , 2007, 207, 118-127.	4.1	51
151	Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 424, 185-189.	2.1	53
152	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. <i>NeuroImage</i> , 2007, 36, 298-312.	4.2	96
153	Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa. <i>Biological Psychiatry</i> , 2007, 61, 1090-1099.	1.3	142
154	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	5.3	465
155	Regional cerebral blood flow after recovery from anorexia or bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2007, 40, 488-492.	4.0	39
156	Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. <i>Synapse</i> , 2007, 61, 523-530.	1.2	61
157	A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. <i>Journal of Neurochemistry</i> , 2007, 102, 2118-2131.	3.9	72
158	Serotonin transporter binding after recovery from eating disorders. <i>Psychopharmacology</i> , 2007, 195, 315-324.	3.1	83
159	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 84-90.	3.6	114
160	The high-affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET. <i>FASEB Journal</i> , 2007, 21, A29.	0.5	0
161	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <i>NeuroImage</i> , 2006, 33, 94-102.	4.2	116
162	Molecular targets. <i>Nuclear Medicine and Biology</i> , 2006, 33, 1.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Discussion of targeting proteins in vivo: in vitro guidelines. Nuclear Medicine and Biology, 2006, 33, 449-451.	0.6	58
164	Radiopharmaceutical space. Nuclear Medicine and Biology, 2006, 33, 829.	0.6	2
165	Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. Journal of NeuroVirology, 2006, 12, 262-271.	2.1	55
166	Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. Journal of Neurology, 2006, 253, 242-247.	3.6	303
167	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β ₄₂ in humans. Annals of Neurology, 2006, 59, 512-519.	5.3	1,190
168	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006, 129, 2805-2807.	7.6	54
169	³⁴ X Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. Methods in Enzymology, 2006, 412, 123-144.	1.0	52
170	Imaging of CNS myelin by positron-emission tomography. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9304-9309.	7.1	139
171	Altered Brain Serotonin 5-HT _{1A} Receptor Binding After Recovery From Anorexia Nervosa Measured by Positron Emission Tomography and [Carbonyl ¹¹ C]WAY-100635. Archives of General Psychiatry, 2005, 62, 1032.	12.3	157
172	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1528-1547.	4.3	622
173	Imaging Inflammation. , 2005, , 445-461.		1
174	Imaging Technology for Neurodegenerative Diseases. Archives of Neurology, 2005, 62, 196.	4.5	69
175	Positron Emission Tomography Agents for Central Nervous System Drug Development Applications. Annual Reports in Medicinal Chemistry, 2005, 40, 49-68.	0.9	4
176	Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neuroscience Letters, 2005, 380, 127-132.	2.1	104
177	Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiology and Behavior, 2005, 85, 73-81.	2.1	149
178	Increased Dopamine D ₂ /D ₃ Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [¹¹ C]Raclopride. Biological Psychiatry, 2005, 58, 908-912.	1.3	314
179	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	3.6	1,839
180	Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid- β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. Journal of Neuroscience, 2005, 25, 10598-10606.	3.6	357

#	ARTICLE	IF	CITATIONS
181	Simplified quantification of PIB amyloid imaging PET studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S589-S589.	4.3	3
182	Anti-A β antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 428-433.	8.2	161
183	PET imaging of 5-HT1A receptors in late-life depression: Relationship to treatment response. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S323-S323.	4.3	0
184	Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1959-72.	5.0	398
185	Serotonin 1A Receptor Binding and Treatment Response in Late-Life Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 2258-2265.	5.4	170
186	Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness. <i>Neuropsychopharmacology</i> , 2004, 29, 1143-1155.	5.4	158
187	Distribution of 1-(2-Deoxy-2-fluoro- β -D-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts. <i>Clinical Cancer Research</i> , 2004, 10, 6669-6676.	7.0	13
188	Development of a PET/SPECT Agent for Amyloid Imaging in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2004, 24, 055-062.	2.3	69
189	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound B. <i>Annals of Neurology</i> , 2004, 55, 306-319.	5.3	3,777
190	In Vivo Imaging of Alzheimer Pathology in Transgenic Mice using Multiphoton Microscopy. <i>Research and Perspectives in Alzheimer's Disease</i> , 2004, , 33-45.	0.1	0
191	Development of Benzothiazole Amyloid-Imaging Agents. , 2004, , 113-122.		1
192	First PET Study with a Benzothiazol Amyloidimaging Agent (PIB) in Alzheimer's Disease Patients and Healthy Volunteers. , 2004, , 123-137.		4
193	P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid. <i>Neurobiology of Aging</i> , 2004, 25, S232-S233.	3.1	12
194	P2-063 In vivo dynamics of amyloid associated neuritic dystrophy before and after anti-A β immunotherapy. <i>Neurobiology of Aging</i> , 2004, 25, S241-S242.	3.1	0
195	P2-156 Development of amyloid-imaging agents for both pet and spect. <i>Neurobiology of Aging</i> , 2004, 25, S270.	3.1	0
196	P2-186 In vivo imaging of prion amyloid deposits. <i>Neurobiology of Aging</i> , 2004, 25, S280-S281.	3.1	0
197	Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. <i>Current Pharmaceutical Design</i> , 2004, 10, 1469-1492.	1.9	237
198	Targeting Prion Amyloid Deposits In Vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 775-784.	1.7	32

#	ARTICLE	IF	CITATIONS
199	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. <i>Journal of Clinical Investigation</i> , 2004, 113, 981-989.	8.2	39
200	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. <i>Journal of Clinical Investigation</i> , 2004, 113, 981-989.	8.2	36
201	Effects of Lipophilicity on the Affinity and Nonspecific Binding of Iodinated Benzothiazole Derivatives. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 255-260.	2.3	47
202	Synthesis and Evaluation of ¹¹ C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2740-2754.	6.4	921
203	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 781-789.	1.0	74
204	Positron emission tomography radiochemistry. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 671-687.	1.0	10
205	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid- β ligand in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12462-12467.	7.1	253
206	Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 1745.	4.5	506
207	The Binding of 2-(4-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component. <i>Journal of Neuroscience</i> , 2003, 23, 2086-2092.	3.6	269
208	Imaging A β Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 797-805.	1.7	366
209	MR atlas of the baboon brain for functional neuroimaging. <i>Brain Research Bulletin</i> , 2002, 58, 429-438.	3.0	36
210	Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. <i>Brain Research</i> , 2002, 927, 97-103.	2.2	27
211	Synthesis and ¹¹ C-labelling of (E,E)-1-(3,4-dihydroxystyryl)-4-(3-methoxy-4-hydroxystyryl) benzene for PET imaging of amyloid deposits?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 647-664.	1.0	22
212	Synthesis and evaluation of 2-(3-Iodo-4-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 11-16.	2.3	56
213	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 295-298.	2.2	343
214	Imaging Amyloid- β Deposits <i>In Vivo</i> . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1035-1041.	4.3	110
215	Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1090-100.	5.0	23
216	Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. <i>Biological Psychiatry</i> , 2001, 49, 81-96.	1.3	650

#	ARTICLE	IF	CITATIONS
217	Visualization of fibrillar amyloid deposits in living, transgenic <i>Caenorhabditis elegans</i> animals using the sensitive amyloid dye, X-34. <i>Neurobiology of Aging</i> , 2001, 22, 217-226.	3.1	147
218	Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. <i>Life Sciences</i> , 2001, 69, 1471-1484.	4.3	408
219	Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons. <i>Synapse</i> , 2001, 41, 1-10.	1.2	33
220	Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. <i>Synapse</i> , 2001, 41, 11-21.	1.2	54
221	Gender-specific aging effects on the serotonin 1A receptor. <i>Brain Research</i> , 2001, 895, 9-17.	2.2	99
222	Serotonin Transporter Binding In Vivo. , 2001, , 265-271.		2
223	Serotonin type-1A receptor imaging in depression. <i>Nuclear Medicine and Biology</i> , 2000, 27, 499-507.	0.6	182
224	Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. <i>Biological Psychiatry</i> , 2000, 48, 854-860.	1.3	152
225	PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum. <i>Neuropsychopharmacology</i> , 1999, 21, 694-709.	5.4	110
226	An efficient synthesis of the precursors of [11C]MDL 100907 labeled in two specific positions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 949-957.	1.0	13
227	Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. <i>Nuclear Medicine and Biology</i> , 1999, 26, 501-507.	0.6	26
228	Pet imaging of serotonin 1A receptor binding in depression. <i>Biological Psychiatry</i> , 1999, 46, 1375-1387.	1.3	598
229	PET Imaging of Serotonin Type 2A Receptors in Late-Life Neuropsychiatric Disorders. <i>American Journal of Psychiatry</i> , 1999, 156, 1871-1878.	7.2	144
230	Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. <i>Brain Research</i> , 1998, 813, 167-171.	2.2	121
231	Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging. <i>Neuropsychopharmacology</i> , 1998, 18, 407-430.	5.4	432
232	Stereoconservative synthesis of the enantiomerically pure precursors of [11C](+)-McN 5652 and [11C]($\hat{\alpha}$)-McN 5652. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998, 41, 9-17.	1.0	8
233	Test-retest variability of serotonin 5-HT _{2A} receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. , 1998, 30, 380-392.		67
234	Characterization of the Radiolabeled Metabolites of [18 F]Altanserin: Implications for Kinetic Modeling. , 1998, , 293-298.		8

#	ARTICLE	IF	CITATIONS
235	Test of retest variability of serotonin 5-HT _{2A} receptor binding measured with positron emission tomography and [¹⁸ F]altanserin in the human brain. <i>Synapse</i> , 1998, 30, 380-392.	1.2	1
236	Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1997, 826, 254-262.	3.8	82
237	High pressure nucleophilic fluoride-ion substitution reactions: formation of fluoroalkylbenzenes. <i>Journal of Fluorine Chemistry</i> , 1996, 78, 121-129.	1.7	10
238	Synthesis of ¹²³ I-and labelled 5-iodo-6-nitroquipazine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994, 34, 905-913.	1.0	16
239	Evaluation of [³ H]paroxetine as an in vivo ligand for serotonin uptake sites: A quantitative autoradiographic study in the rat brain. <i>Synapse</i> , 1993, 13, 1-9.	1.2	24
240	[¹²⁵ I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. I. In vitro studies. <i>Brain Research</i> , 1993, 619, 229-235.	2.2	39
241	[¹²⁵ I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. II. In vivo studies in rats. <i>Brain Research</i> , 1993, 619, 236-246.	2.2	41
242	In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [¹²³ I]5-iodo-6-nitroquipazine. <i>European Journal of Pharmacology</i> , 1993, 242, 189-193.	3.5	37
243	Synthesis and evaluation of high affinity, aryl-substituted [¹⁸ F]fluoropropylbenzamides for dopamine D-2 receptor studies. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 571-588.	0.3	3
244	[¹²⁵ I]5-iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. <i>European Journal of Pharmacology</i> , 1992, 210, 103-104.	3.5	32
245	Quantitative in vitro and ex vivo autoradiography of the α_2 -adrenoceptor antagonist [³ H]atopamezole. <i>European Journal of Pharmacology</i> , 1992, 224, 27-38.	3.5	29
246	Synthesis of 2,3-dimethoxy-5-iodobenzoic acid. <i>Journal of Organic Chemistry</i> , 1991, 56, 5451-5456.	3.2	19
247	Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D ₂ receptors. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 1612-1624.	6.4	41
248	Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1991, 11, 323-330.	4.3	167
249	Fluoroalkylbenzenes: Synthesis of (S)-2,3-Dimethoxy-5-[(3-fluoro)propyl-6-hydroxy-N-(1-ethyl-2-pyrrolidinyl)methyl]benzamide. <i>Journal of Fluorine Chemistry</i> , 1991, 51, 149-152.	1.7	12
250	Synthesis of 1-[2,5-dimethoxy-4-(² -fluoroethyl)phenyl]-2-aminopropane: studies related to ¹⁸ F-labelled serotonin receptor ligands. <i>Tetrahedron Letters</i> , 1988, 29, 6537-6539.	1.4	9
251	Synthesis and in vivo evaluation of ¹²² I- and ¹³¹ I-labelled iodoperidol, a potential agent for the tomographic assessment of cerebral perfusion. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1987, 14, 91-98.	0.3	11
252	Synthesis of ¹²² I- and ¹²⁵ I-labelled meta-dimethoxy-N,N-dimethyliodophenylisopropylamines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1986, 23, 115-125.	1.0	11

#	ARTICLE	IF	CITATIONS
253	Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. <i>Journal of Medicinal Chemistry</i> , 1984, 27, 1071-1077.	6.4	19
254	Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type. <i>Journal of Computer Assisted Tomography</i> , 1983, 7, 590-598.	0.9	434